Non-emergent hemoptysis in patients with primary or metastatic lung tumors: The role of transarterial embolization

IF 3.2 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

European Journal of Radiology Pub Date : 2024-10-12 DOI:10.1016/j.ejrad.2024.111786

Ruben Geevarghese , Elena Petre , Etay Ziv , Ernesto Santos , Lee Rodriguez , Ken Zhao , Vlasios S. Sotirchos , Stephen B. Solomon , Erica S. Alexander

{"title":"Non-emergent hemoptysis in patients with primary or metastatic lung tumors: The role of transarterial embolization","authors":"Ruben Geevarghese , Elena Petre , Etay Ziv , Ernesto Santos , Lee Rodriguez , Ken Zhao , Vlasios S. Sotirchos , Stephen B. Solomon , Erica S. Alexander","doi":"10.1016/j.ejrad.2024.111786","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the role of systemic arterial embolization for the management of non-emergent hemoptysis in patients with primary or metastatic lung tumors.</div></div><div><h3>Materials and methods</h3><div>This is a retrospective single center study of consecutive patients who underwent systemic arterial embolization for non-emergent hemoptysis between 2011 and 2023. Study endpoints included technical success, clinical success (partial or complete resolution of hemoptysis) and overall survival. Hemoptysis-free and overall survival were estimated using the Kaplan-Meier method. Predictive factors for hemoptysis-free survival and overall survival were evaluated using univariate analysis (Cox regression). Post-procedural 30-day adverse events were recorded in line with Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</div></div><div><h3>Results</h3><div>A total of 30 patients were identified. Technical success was achieved in 24/30 (80 %) patients. Clinical success following embolization was achieved in 23/30 (76.7 %) patients. Median length of hospitalization was 5 days (Range: 1 to 16 days). Median overall survival was 194 days (95 % CI: 89 to 258). Median hemoptysis-free survival was 286 days (95 % CI: 42 to not reached). No significant clinical or procedural predictors of hemoptysis-free survival or overall survival were identified. Serious adverse events (CTCAE Grade > 3) occurred in 1 patient (3.4 % − fatal respiratory failure).</div></div><div><h3>Conclusion</h3><div>Embolization of non-emergent hemoptysis in patients with lung malignancies is safe and effective. Recurrence is however high in this patient population, likely due to the nature of the underlying disease.</div></div>","PeriodicalId":12063,"journal":{"name":"European Journal of Radiology","volume":"181 ","pages":"Article 111786"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Radiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0720048X24005023","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To evaluate the role of systemic arterial embolization for the management of non-emergent hemoptysis in patients with primary or metastatic lung tumors.

Materials and methods

This is a retrospective single center study of consecutive patients who underwent systemic arterial embolization for non-emergent hemoptysis between 2011 and 2023. Study endpoints included technical success, clinical success (partial or complete resolution of hemoptysis) and overall survival. Hemoptysis-free and overall survival were estimated using the Kaplan-Meier method. Predictive factors for hemoptysis-free survival and overall survival were evaluated using univariate analysis (Cox regression). Post-procedural 30-day adverse events were recorded in line with Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Results

A total of 30 patients were identified. Technical success was achieved in 24/30 (80 %) patients. Clinical success following embolization was achieved in 23/30 (76.7 %) patients. Median length of hospitalization was 5 days (Range: 1 to 16 days). Median overall survival was 194 days (95 % CI: 89 to 258). Median hemoptysis-free survival was 286 days (95 % CI: 42 to not reached). No significant clinical or procedural predictors of hemoptysis-free survival or overall survival were identified. Serious adverse events (CTCAE Grade > 3) occurred in 1 patient (3.4 % − fatal respiratory failure).

Conclusion

Embolization of non-emergent hemoptysis in patients with lung malignancies is safe and effective. Recurrence is however high in this patient population, likely due to the nature of the underlying disease.

查看原文本刊更多论文

原发性或转移性肺肿瘤患者的非突发咯血：经动脉栓塞术的作用。

目的：评估全身动脉栓塞治疗原发性或转移性肺肿瘤患者非突发咯血的作用：这是一项回顾性单中心研究，研究对象为2011年至2023年间因非急性咯血而接受全身动脉栓塞治疗的连续患者。研究终点包括技术成功率、临床成功率（咯血部分或完全止住）和总生存率。无咯血生存率和总生存率采用 Kaplan-Meier 法进行估算。采用单变量分析（Cox 回归）评估了无咯血生存率和总生存率的预测因素。根据《不良事件通用术语标准》（CTCAE）v5.0 版记录了手术后 30 天的不良事件：共确定了 30 名患者。24/30（80%）名患者取得了技术成功。23/30（76.7%）名患者在栓塞术后取得了临床成功。住院时间中位数为 5 天（范围：1 至 16 天）。总生存期中位数为 194 天（95 % CI：89 至 258 天）。无咯血生存期中位数为 286 天（95 % CI：42 天至未达到）。未发现无咯血生存期或总生存期的重要临床或程序预测因素。1名患者（3.4% - 致命性呼吸衰竭）发生了严重不良事件（CTCAE等级> 3）：结论：对肺部恶性肿瘤患者的非急性咯血进行栓塞治疗是安全有效的。结论：对肺部恶性肿瘤患者进行非突发咯血栓塞治疗是安全有效的，但这类患者的复发率较高，这可能与潜在疾病的性质有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Radiology 医学-核医学

CiteScore

6.70

自引率

3.00%

发文量

398

审稿时长

42 days

期刊介绍： European Journal of Radiology is an international journal which aims to communicate to its readers, state-of-the-art information on imaging developments in the form of high quality original research articles and timely reviews on current developments in the field. Its audience includes clinicians at all levels of training including radiology trainees, newly qualified imaging specialists and the experienced radiologist. Its aim is to inform efficient, appropriate and evidence-based imaging practice to the benefit of patients worldwide.